Vernalis’ lead cough cold product (TuzistraTM XR) was approved by the FDA on 30th April and the company is currently making preparations for a full commercial launch later this year, in time for the US ‘flu season’. Although the four subsequent cough cold programmes are experiencing formulation delays, we have upgraded our valuation based on the results of payer and market research, which suggests better pricing and a larger initial target group of prescribers than previously expected. We are up ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Valuation upgrade
Vernalis’ lead cough cold product (TuzistraTM XR) was approved by the FDA on 30th April and the company is currently making preparations for a full commercial launch later this year, in time for the US ‘flu season’. Although the four subsequent cough cold programmes are experiencing formulation delays, we have upgraded our valuation based on the results of payer and market research, which suggests better pricing and a larger initial target group of prescribers than previously expected. We are up ....